Significance of proteomic fingerprints on shifting the NSCLC patients with Gefltinib
10.3760/cma.j.issn.1006-9801.2009.06.011
- VernacularTitle:表面增强激光解析电离技术筛选吉非替尼治疗非小细胞肺癌优势患者的验证报告
- Author:
Shuxiang SUN
;
Shouxi HU
;
Huachao ZHOU
;
Yi PEI
- Publication Type:Journal Article
- Keywords:
Carcinoma,non-small-cell lung;
Drug screening assays;
SELDI-TOF-MS
- From:
Cancer Research and Clinic
2009;21(6):393-395
- CountryChina
- Language:Chinese
-
Abstract:
Objective Verification of the serum proteomic fingerprints of NSCLC (non-small cell lung cancer) patients related to their advantage in Gefitinib therapy. Methods 27 NSCLC patients who have been treated with Gefitinib for more than 1 month and attained certain efficacy were taken for examination. They were divided into 3 groups, CR+PR, SD and PD, according to the evaluation criteria of solid tumor curative efficacy. All patients received SELDI (SELDI-TOF-MS surface-enhanced laser desorption/ionization time-of-flight mass spectrometry technique) inspection before treatment with Gefitinib. The shifting procedure was based on the abundance of the fingerprint :"M/Z 8693 50H+". According to the abundance of this fingerprint founded, the patients were divided into 4 populations: 1. The advantage population (10 patients, abundance 10 %);2. The disadvantage population (7 patients, abundance≥30 %);3. Suspected population A (5 patients, abundance 11%-15 %);4. Suspected population B (5 patients, abundance 16～ 29%). The ratio of patients in each of the 3 groups (CR + PR, SD and PD) into each of the above 4 populations were analyzed. Results It showed that: 1. In the advantage population, the ratio dispersed from CR + PR group is 9/10, those from SD group is 1/10 and from PD is 0.2. In the disadvantage population, the ratio dispersed from CR + PR group is 1/7, those from SD group is 1/7 and from PD is 5/7. In the suspected A group, the ratio from CR + PR group is 3/5, those from SD group is 1/5 and from PD is 1/5. 4. In the suspected B group, the ratio from CR + PR group is 3/5, those from SD group is 1/5 and from PD is 1/5. Conclusion This fingerprint "M/Z 8693 50H+" with abundance 10% after SELDI inspection is the index choosing advantage patients suitable to receive Gefitinib therapy.
